KORU Medical Systems Reports 18.2% Revenue Growth in Q2 2026

KORU Medical Systems, Inc. reported a significant increase in financial performance for the second quarter of 2026, with net revenues reaching $12.0 million, an 18.2% increase from $10.2 million in the same period last year. The growth was primarily driven by a 12.4% rise in domestic core revenues, totaling $8.0 million, and a substantial 59.1% increase in international core revenues, which amounted to $3.5 million. However, the company experienced a 35% decline in its pharma services and clinical trials segment, contributing $0.6 million to total revenues. Gross profit for the quarter was $7.8 million, reflecting a 21.2% increase compared to $6.5 million in the prior year, resulting in a gross margin of 65.1%, up from 63.5%.

For the first half of 2026, KORU Medical reported total revenues of $23.8 million, a 20.1% increase from $19.8 million in the same period of 2025. Domestic core revenues increased by 12.1% to $15.7 million, while international core revenues surged by 46.5% to $6.8 million. The pharma services and clinical trials segment also saw a modest increase of 11.8%, totaling $1.3 million. Despite the revenue growth, the company reported a net loss of $554,629 for the first half, an improvement from a loss of $1.4 million in the same period last year, primarily due to increased gross profit offsetting higher operating expenses.

Operationally, KORU Medical's total operating expenses for the second quarter were $7.2 million, a 6.3% increase from $6.8 million in the previous year. This increase was driven by higher selling, general, and administrative expenses, which rose by 10.3% to $5.9 million, attributed to increased compensation and legal fees. Research and development expenses decreased by 10.5% to $1.1 million, reflecting lower project spending. The company’s cash position at the end of June 2026 was $8.3 million, down from $8.9 million at the end of 2025, while inventory increased to $4.5 million, indicating preparations for anticipated demand.

In terms of strategic developments, KORU Medical has been focusing on expanding its market presence, particularly in international markets, which contributed significantly to revenue growth. The company has also been investing in research and development to enhance its product offerings, including the FREEDOM™ System for subcutaneous drug delivery. Additionally, KORU Medical amended its credit facility in March 2026, extending the maturity of its revolving credit and term loan facilities, which provides additional financial flexibility.

Looking ahead, KORU Medical anticipates continued growth driven by new patient starts and market share gains, particularly in the subcutaneous immunoglobulin market. The company is also exploring opportunities for geographic expansion and product adoption, while remaining cautious of potential market challenges such as inflation and supply chain disruptions. The management believes that the current cash position, along with cash flows from operations, will be sufficient to meet the company's needs for at least the next twelve months, although future capital requirements may necessitate additional financing.